Q-omics provides the consensus-scored FZD4-DT profile across patient tissues and cancer cell-line models. FZD4-DT expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FZD4-DT is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, FZD4-DT RNA expression shows 18,177 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where FZD4-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FZD4-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FZD4-DT survival associations across molecular data types. FZD4-DT RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FZD4-DT RNA expression–survival associations across cancer types. High FZD4-DT expression shows unfavorable associations in CESC and LGG, but favorable associations in KIRC, UCS, MESO and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FZD4-DT RNA expression.
This table summarizes FZD4-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for FZD4-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FZD4-DT shows lower tumor expression in THCA, COAD, KICH, BRCA and READ and higher tumor expression in KIRC. The THCA box plot shows higher FZD4-DT RNA expression in normal versus tumor tissue (log2 FC = −0.657, t-test p < 0.001).
This table shows molecular features associated with FZD4-DT in patient tissues and cancer cell lines. In patient samples, FZD4-DT shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
